Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Drug uptake in cytoplasm of human CCD18 cells at 50 uM by fluorescence microscopy
Assay data:1 Active, 1 Tested
SummaryCompounds, Active
Drug uptake in cytoplasm of human HCT116 cells at 50 uM by fluorescence microscopy
Antiproliferative activity against human MDA-MB-468 cells assessed as cell viability at 50 uM after 72 hrs by MTS assay (Rvb = 100 +/- 8.06%)
Assay data:8 Tested
Summary
Antiproliferative activity against human HCT116 cells assessed as cell viability at 50 uM after 72 hrs by MTS assay (Rvb = 100 +/- 6.01%)
Antiproliferative activity against human CCRF-CEM cells assessed as cell viability at 50 uM after 72 hrs by MTS assay (Rvb = 100 +/- 5.54%)
Inhibition of SIRT1 in human HCT116 cells assessed as increase in p53 acetylation incubated for 24 hrs by Western blotting method in presence of etoposide
Assay data:1 Tested
SummaryRelated BioAssays by Target
Inhibition of SIRT2 in human HCT116 cells assessed as increase in alpha-tubulin acetylation up to 50 uM incubated for 24 hrs by Western blotting method
SummaryCompounds, ActiveRelated BioAssays by Target
Inhibition of SIRT1 in human HCT116 cells assessed as increase in p53 acetylation up to 50 uM incubated for 24 hrs by Western blotting method
Aqueous solubility of compound in water containing 0.5% DMSO by UV-spectrophotometry analysis
Competitive inhibition of recombinant human C-terminal His-tagged SIRT2 (13 to 319 residues) using human p53 derived peptides as substrate incubated for 45 mins by fluorescence assay in presence of increasing NAD+ level
Reversible inhibition of recombinant human C-terminal His-tagged SIRT2 (13 to 319 residues) using human p53 derived peptides as substrate at 10 uM incubated for 45 mins by fluorescence assay
Reversible inhibition of recombinant human N-terminal GST-tagged SIRT1 (193 to 741 residues) using human p53 derived peptides as substrate at 10 uM incubated for 45 mins by fluorescence assay
Inhibition of recombinant human C-terminal His-tagged SIRT2 (13 to 319 residues) using human p53 derived peptides as substrate incubated for 45 mins by fluorescence assay
Assay data:2 Active, 11 Tested
Inhibition of recombinant human C-terminal His-tagged SIRT2 (13 to 319 residues) using human p53 derived peptides as substrate at 50 uM incubated for 45 mins by fluorescence assay
Assay data:11 Tested
Inhibition of recombinant human N-terminal GST-tagged SIRT1 (193 to 741 residues) using human p53 derived peptides as substrate incubated for 45 mins by fluorescence assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 11 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition of recombinant human N-terminal GST-tagged SIRT1 (193 to 741 residues) using human p53 derived peptides as substrate at 50 uM incubated for 45 mins by fluorescence assay
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on